TrueBeam Linear Accelerator Research Articles

Evaluation of myQA SRS detector for the stereotactic treatment plan verification

Modern radiotherapy techniques involve the use of high-modulated radiation fields. Intensity Modulated Radiation Therapy and Volumetric Modulated Arc Therapy require careful quality control to ensure that the planned dose distributions can be delivered by the treatment system. Quality assurance of the patient-specific treatment plan is often performed prior to treatment, when beams are delivered to the phantom and radiation doses are checked compared to the doses provided in the treatment planning system. In this study, myQA SRS measurements were compared to the EBT3 film measurements. The resolution of the film is 25 µm. The sufficiently high resolution of the stereotactic radiosurgery (SRS) detector (0.4 mm) makes it a potential alternative to film for real-time dosimetry. Irradiation was performed on a Varian TrueBeam linear accelerator. The gamma index criteria were 3 %/3 mm, the threshold dose was 10 %, and gamma index normalization was performed using the global maximum dose. The gamma index results obtained on film and on myQA SRS gave comparable results. The passing rate of film measurements based on gamma evaluation was 89.92 % and the passing rate of myQA SRS was 82.6 %. The average gamma values for the 3 %/3 mm global gamma analysis were 0.48 for the film and 0.594 for myQA SRS. In this study, film was chosen as the reference clinical detector with the highest resolution available today. myQA SRS, designed for verification of stereotactic plans, qualitatively and quantitatively identified areas of dose mismatch.

Feasibility of volumetric-modulated arc therapy gating for cardiac radioablation using real-time ECG signal acquisition and a dynamic phantom.

Stereotactic arrythmia radioablation (STAR) is a noninvasive technique to treat ventricular tachycardia (VT). Management of cardiorespiratory motion plays an essential role in VT-STAR treatments to improve treatment outcomes by reducing positional uncertainties and increasing dose conformality. Use of an electrocardiogram (ECG) signal, acquired in real-time, as a surrogate to gate the beam has the potential to fulfil that intent. To investigate the gated delivery of volumetric-modulated arc therapy (VMAT) for STAR on a TrueBeam linear accelerator (linac) using a real-time acquired ECG signal and a dynamic cardiac phantom. Dosimetric characteristics of a 6 MV flattening filter free (FFF) beam from a Varian TrueBeam linac were initially evaluated under high-frequency gating scenarios relevant to cardiac rhythms with respect to dose linearity, beam output, and energy quality. A microcontroller board was used to interface and gate the linac, sending a beam on/off signal. For real-time cardiac gated measurements, an AD8232 Heart Monitor board was used to acquire the ECG signal and synchronize the VMAT delivery to an ArcCHECK detector to a specific phase of the cardiac cycle. Gated dose distributions were compared against those acquired for a non-gated delivery mode. An in-house dynamic cardiac phantom was developed to simulate cardiorespiratory motion that correlates target position with the signal to gate the beam. Measured dose distributions using gafchromic film were also compared against the static (reference) mode in different scenarios with and without gating. Maximum difference in dose per monitor unit (MU) was found to be no greater than 1% as compared to static mode with variation in the chamber response within 0.2% in the range of 50 MUs to 200 MUs. Maximum percentage differences for the beam output and beam qualiy index (TPR20,10) between gated and non-gated modes were 0.91% and -0.44%, respectively. Comparison of delivered dose distributions for the VMAT plan without gating versus ECG synchronized gating modes provided a passing rate 98% for the gamma analysis with 1% relative dose difference, 1mm distance-to-agreement criteria. For the synchronization of dose delivery with target position, passing rates were 98%, 97%, and 99% for the axial, coronal, and sagittal planes, respectively, when gating the beam based on target position for cardiac motion only, for 3%, 3mm tolerance as compared to static mode. Without gating the beam, passing rates of the respective plans are 97%, 94%, and 99% for the cardiac motion only, and 67%, 57%, and 55% when including respiratory component of motion. A 6 MV-FFF TrueBeam is stable for performing gating in STAR under high-frequency gate windows within typical cardiac cycles. Agreement between measured dose distributions for a VMAT plan in static and ECG-synchronized deliveries and between static and target-position gated modes shows that the proposed methodology is feasible and can be implemented on a TrueBeam platform.

A multi-institutional trial evaluating the use of an integrated quality assurance phantom for frameless single-isocenter multitarget stereotactic radiosurgery.

Brain radiosurgery treatments require multiple quality-assurance (QA) procedures to ensure accurate and precise treatment delivery of ablative doses. As single-isocenter multitarget radiosurgery treatments become more popular for treating patients with multiple brain metastases, quantifying off-axis accuracy of linear accelerators is crucial. In this study, we developed a novel brain radiosurgery integrated phantom and validated this phantom at multiple institutions to enable radiosurgery QA with a single phantom to facilitate implementation of a frameless single-isocenter, multitarget radiosurgery program. The phantom combines multiple independent verification system tests including the Winston-Lutz test, off-axis accuracy evaluation (i.e., off-axis Winston-Lutz), as well as dosimetric measurements utilizing both point dose and film measurement. A novel 3D-printed phantom, coined OneIso, was designed with a movable insert which can switch between Winston-Lutz test targets and dose measurement without moving the phantom itself. In total, four phantoms were printed, and eight institutions participated in this study, which included both Varian TrueBeam (n=6) and Elekta Versa (n=2) linear accelerators. For off-axis Winston-Lutz measurements, a row of off-axis ball-bearings (BBs) was integrated into the OneIso. To quantify the spatial accuracy versus distance from isocenter, two-dimensional displacements were calculated between the planned and delivered BB locations relative to their respective MLC-defined field borders. For dose verification, brain radiosurgery clinical treatment plans previously treated were delivered at multiple cancer centers (six of eight centers). Radiochromic film and pinpoint ion chamber comparison measurements were obtained with OneIso. Dose verification performed using the OneIso phantom across the different centers were all within on average 3% agreement, for both film and point-dose measurements. OneIso identified a reduction in spatial accuracy further away from isocenter for all eight radiosurgery machines. Differences increased as distance from isocenter increased, exceeding recommended radiosurgery accuracy tolerances (<1mm) at different distances for each machine (2-7cm), indicating that the tolerance is machine-dependent. OneIso provides a streamlined, single-setup workflow for single-isocenter multitarget frameless linac-based radiosurgery QA that can be easily translated to multiple institutions. Additionally, quantifying off-axis spatial discrepancies allows for determination of the maximum distance between targets and iso that meet single-isocenter multitarget radiosurgery program recommendations.

Long-term performance monitoring of a-Si 1200 electronic portal imaging device for dosimetric applications.

Recently, dosimetri applications of the electronic portal imaging device (EPID) in radiotherapy have gained popularity. Confidence in the robust and reliable dosimetric performance of EPID detectors is essential for their clinical use. This study aimed to evaluate the dosimetric performance of the a-Si 1200 EPID and assess the long-term stability of its response. Weekly measurements were performed on two clinically used TrueBeam linear accelerators (linacs) equipped with a-Si 1200 EPID detectors over a 2-year period. They included dark and flood calibration fields, and EPID response to an open field corrected for the long-term machine output drift measured with the secondary absolute dosimeters: an ion chamber and an ion chamber array. All measurements were performed using five photon beam energies and two imaging modes: continuous and dosimetry. The measurements were analyzed for constancy and the presence of long-term trends. Comparisons were made between the two linacs for each beam energy. Pixel sensitivity matrices (PSM) were determined semi-annually and analyzed for long-term constancy for both treatment machines. The long-term variation of the dark and flood field signals, integrated across the EPID plane, over the entire observation period did not exceed 0.17% and 0.79%, respectively. The output-corrected EPID response showed long-term variation from 0.28% to 0.36%, depending on beam energy, while the short-term variation was 0.04%-0.07% for EPID and 0.02%-0.06% for secondary dosimeters. The long-term variation of secondary dosimeters was 0.2%-0.3%. PSMs were found to be stable to within 1% for 97.8% of pixels and 2% for 100% of pixels. Techniques to monitor and assess the long-term performance of the a-Si 1200 EPID as a dosimeter were developed and implemented using two TrueBeam linacs. The long-term variation of the EPID response was within clinical tolerance indicated in AAPM TG-142 report, and the detector was shown to be stable and reproducible for routine clinical dosimetry.

Evaluating the Transmission Type Reference Chamber for Small Field Dosimetry

AbstractTo assess the efficacy of a transmission‐type parallel plane reference chamber (T‐REF) for small‐field percentage depth dose (PDD) measurements using two high‐resolution detectors. The study utilizes microSilicon and microDiamond detectors for small‐field measurements, both with and without a T‐REF reference chamber. TrueBeam linear accelerator provides various photon energies (6X, 6XFFF, 10X, 10XFFF) for depth dose measurements. A sun‐nuclear 3D water tank is used to measure the PDD up to a depth of 15 cm. Analysis of the data includes a 1D gamma passing rate calculated using an in‐house MATLAB program. The study compares the PDD measurements obtained with and without the T‐REF. The T‐REF exhibits negligible beam perturbations across different field sizes and energies. The overall maximum mean PDD differences are 0.31 ± 0.16% for microSilicon and 0.33 ± 0.17% for microdiamond. The overall mean 1D gamma passing rate is 99.6 ± 0.2%. This study demonstrates that the T‐REF is a reliable and effective reference detector for small‐field radiation dosimetry.

Dosimetric evaluation and gradient analysis of various MLC leaf-width effects in external beam radiation therapy: TrueBeam Vs Halcyon

IntroductionThis study investigates dosimetric influence and gradient-analysis of leaf-width of various Multi-leaf-collimators (MLC) from Truebeam and Halcyon linear accelerators. MethodsThe leaf-width effects of Millennium120 and HD120MLC from Truebeam and SX1 and SX2 from Halcyon were studied using virtual phantom in Eclipse16.1.2 TPS. Target structures consist of bore and wave cylinders of equally spaced projected Planning target volume (PTV) of diameters ranging from 1-to-5 cm and 20 cm length. Treatment plans for all PTVs, and four different MLCs configurations from both machines were created utilizing 6MVFFF beam to deliver dose of 50Gy/25# using IMRT and VMAT. Plans were evaluated using plan quality indices including dose conformity, homogeneity, gradient radius, and Monitor-unit (MU). Also, dose gradients were analyzed by estimating distinct integral volume VD% and paired-t-tests were performed to evaluate statistical differences. ResultsAll the plan satisfied the minimum criteria of D95 %≥prescription dose and V107 %≤2cc. Mean conformity and homogeneity indices for SX1MLC(CI = 0.680,HI = 0.022) were found significantly higher and lower than SX2(CI = 0.746,HI = 0.016), Millennium120 (CI = 0.739,HI = 0.012), and HD120MLC(CI = 0.745,HI = 0.017), respectively. However, CI and HI for SX2, Millennium120, and HD120MLC found comparable. Gradient radius enclosing 50 % of isodose observed maximum and minimum for SX1 and HD120MLC, respectively. Plan MUs for Truebeam MLCs were found approximately 25 % higher than Halcyon MLCs. Dose distribution generated using SX2 and Millennium120 found comparable, however p ≤ 0.05 ascertained substantial differences among SX1, Millennium120, and HD120MLC. ConclusionMLC leaf-width influences intensity-modulation and significantly alters dosimetric outcome depending on the magnitude of the leaf-width. HD120MLC does not show much significant advantages over SX2 and Millennium120 except gradient control. Implications for practiceHalcyon SX1MLC produces least effective plan compared to all other MLC types. However, SX2 and Millennium120 can produce plans of comparable quality except plan MUs difference.

Small field measurements using electronic portal imaging device

Purpose/Objective. Small-field measurement poses challenges. Although many high-resolution detectors are commercially available, the EPID for small-field dosimetry remains underexplored. This study aimed to evaluate the performance of EPID for small-field measurements and to derive tailored correction factors for precise small-field dosimetry verification. Material/Methods. Six high-resolution radiation detectors, including W2 and W1 plastic scintillators, Edge-detector, microSilicon, microDiamond and EPID were utilized. The output factors, depth doses and profiles, were measured for various beam energies (6 MV-FF, 6 MV-FFF, 10 MV-FF, and 10 MV-FFF) and field sizes (10 × 10 cm2, 5 × 5 cm2, 4 × 4 cm2, 3 × 3 cm2, 2 × 2 cm2, 1 × 1 cm2, 0.5 × 0.5 cm2) using a Varian Truebeam linear accelerator. During measurements, acrylic plates of appropriate depth were placed on the EPID, while a 3D water tank was used with five-point detectors. EPID measured data were compared with W2 plastic scintillator and measurements from other high-resolution detectors. The analysis included percentage deviations in output factors, differences in percentage for PDD and for the profiles, FWHM, maximum difference in the flat region, penumbra, and 1D gamma were analyzed. The output factor and depth dose ratios were fitted using exponential functions and fractional polynomial fitting in STATA 16.2, with W2 scintillator as reference, and corresponding formulae were obtained. The established correction factors were validated using two Truebeam machines. Results. When comparing EPID and W2-PSD across all field-sizes and energies, the deviation for output factors ranged from 1% to 15%. Depth doses, the percentage difference beyond dmax ranged from 1% to 19%. For profiles, maximum of 4% was observed in the 100%–80% region. The correction factor formulae were validated with two independent EPIDs and closely matched within 3%. Conclusion. EPID can effectively serve as small-field dosimetry verification tool with appropriate correction factors.

Clinical applicability of Linac-integrated CBCT based NIPAM 3D dosimetry: a dual-institutional investigation

Objective. To develop and benchmark a novel 3D dose verification technique consisting of polymer gel dosimetry (PGD) with cone-beam-CT (CBCT) readout through a two-institution study. The technique has potential for wide and robust applicability through reliance on CBCT readout. Approach. Three treatment plans (3-field, TG119-C-shape spine, 4-target SRS) were created by two independent institutions (Institutions A and B). A Varian Truebeam linear accelerator was used to deliver the plans to NIPAM polymer gel dosimeters produced at both institutions using an identical approach. For readout, a slow CBCT scan mode was used to acquire pre- and post-irradiation images of the gel (1 mm slice thickness). Independent gel analysis tools were used to process the PGD images (A: VistaAce software, B: in-house MATLAB code). Comparing planned and measured doses, the analysis involved a combination of 1D line profiles, 2D contour plots, and 3D global gamma maps (criteria ranging between 2%1 mm and 5%2 mm, with a 10% dose threshold). Main results. For all gamma criteria tested, the 3D gamma pass rates were all above 90% for 3-field and 88% for the SRS plan. For the C-shape spine plan, we benchmarked our 2% 2 mm result against previously published work using film analysis (93.4%). For 2%2 mm, 99.4% (Institution A data), and 89.7% (Institution B data) were obtained based on VistaAce software analysis, 83.7% (Institution A data), and 82.9% (Institution B data) based on MATLAB. Significance. The benchmark data demonstrate that when two institutions follow the same rigorous procedures gamma passing rates up to 99%, for 2%2 mm criteria can be achieved for substantively different treatment plans. The use of different software and calibration techniques may have contributed to the variation in the 3D gamma results. By sharing the data across institutions, we observe the gamma passing rate is more consistent within each pipeline, indicating the need for standardized analysis methods.

Implementation of an ionization chamber array for linear accelerator monthly dosimetry QA.

The IC Profiler (ICP) manufactured by Sun Nuclear Corporation (SNC) is an ionization chamber (IC) array used for linear accelerator dosimetry measurements. Previous work characterized response of the ICP under various conditions, but there is limited work of its implementation into monthly QA measurement procedures. This work quantifies ICP accuracy and variables that affect accuracy for beam output measurements, and demonstrates feasibility of using the ICP for all recommended monthly dosimetry measurements. A total of 1985 output measurements on six Varian TrueBeam and Edge linear accelerators were performed using three ICP with quad wedges (QWs) and were compared with conventional IC measurements. The accuracy of the ICP for beam output was characterized as the difference between the ICP and IC. Variables that affect ICP accuracy, including gain settings, calibrations, and template baselining as well as machine or energy-specific bias were investigated. Measurements of profile constancy, energy, dose rate constancy, wedge factors, and gating were performed. The initially observed mean output difference between the ICP and IC was 0.16% (0.61%). When gain settings were optimized, the output difference accuracy improved to -0.02% (0.38%). The output accuracy of the ICP was not dependent on array, dose, temperature and pressure calibrations, or template baselining. Statistically, ICP output accuracy was dependent on machine and beam energy, but clinically, all measurements fell within 0.5% of unity. ICP measurements of energy, dose rate constancy, and wedge factors matched passing results with conventional IC in water measurements. Gating and beam profile constancy measurements demonstrated good stability using the ICP. Finally, monthly dosimetry QA using ICP was completed in an average of 33 min compared to 66 min using the IC. This work demonstrated the feasibility and efficiency of using the ICP, with specific considerations, as a measurement device for dosimetric linear accelerator monthly QA.

Accuracy of Beamscan Software in Determining the Inflection Point from the FFF Beam Profile Using Several Array Detectors.

The goal of this study is to determine the accuracy of the PTW Beamscan program in determining the inflection point from Flattening Filter Free Beam Profile utilizing Multiple Detectors. True Beam Linear Accelerator with 6FFF and 10FFF Photon Energies and 10 cm, 15 cm and 20 cm Field Sizes were used for this study. Profile measurements were taken with PTW's 729, 1,500, and 1,600 and the Starcheck system, the Pinpoint 3D with Beamscan system, and Linac's EPID. The first-order derivative was utilized in both the Excel spreadsheet and Beamscan software to analyse raw measured data to locate inflection point and the FWHM was calculated. The accuracy of inflection points and FWHM between the Excel sheet calculation and the software program were investigated. For 10X10 cm2 in the 729 Array, the greatest differences in FWHM were 5.16 mm and 5.04 mm for the X6 FFF and X10 FFF Energies, respectively. The largest difference was 2.26 mm for 1,600 SRS arrays with a 15×15 cm2 field size. The difference in FWHM between Manual and software analysis for 10X10 cm2 and 20X20 cm2 Field Sizes is in decreasing order for detectors from 729, 1,500, 1,600 SRS, Starcheck, Pinpoint 3D, and EPID. In contrast, there is no climbing or declining pattern detected in the difference in Field Width for the 15×15 cm2 Field Size. Similarly, for all detectors except the 1,600 SRS array, the peak of the first-order derivative occurs at the chamber position for a 15X15 cm2 field size. The higher resolution of measurement yields more accuracy in inflection point and the FWHM. Irrespective of measurement resolution, the Beamscan software provided the FWHM closer to the respective nominal Field Size. Out of all detectors, results obtained with Excel Starcheck and EPID are good in agreement with values obtained by the software analysis. Thus, it is shown that Beamscan software is so accurate in determining inflection point of a FFF beam profile and used for routine profile analysis.

Simulating the head of a TrueBeam linear particle accelerator and calculating the photoneutron spectrum on the central axis of a 10-MV photon using particle and heavy-ion transport system code.

Photon energy is higher than the (γ,n) threshold, allowing it to interact with the nuclei of materials with high z properties and liberate fast neutrons. This represents a potentially harmful source of radiation for humans and the environment. This study validated the Monte Carlo simulation, using the particle and heavy-ion transport code system (PHITS) on a TrueBeam 10-MV linear particle accelerator's head shielding model and then used this PHITS code to simulate a photo-neutron spectrum for the transport of the beam. The results showed that, when comparing the simulated to measured PDD and crosslines, 100% of the γ-indexes were<1 (γ3%/3mm) for both simulations, for both phase-space data source and a mono energy source. Neutron spectra were recorded in all parts of the TrueBeam's head, as well as photon neutron spectra at three points on the beamline.

Patient-specific quality assurance in SBRT treatments using 3D polymer gel dosimetry

In stereotactic body radiation therapy (SBRT), patient-specific quality assurance (PSQA) is required due to the complex dose distributions delivered. In this context, polymer gels are considered reliable as a three-dimensional dosimeter. This work used polymer MAGIC-gel sealed in 2 mm thin-wall glass spheres to assess the three-dimensional (3D) dose distribution imparted to patients and compared the results with that provided by the treatment planning system. Four SBRT treatments targeting vertebral, ilium, pelvic lymph node and lung regions were selected for this study. A computed tomography (CT) scan of each glass sphere was obtained, and the patient treatment plan was superimposed on the glass sphere CT image. Thereafter, the spheres were irradiated under similar conditions to the patient using a Varian TrueBeam linear accelerator. A high-spatial resolution optical CT scanner was used to read the glass sphere containing the gel. Planned and delivered 3D dose distributions were compared quantitatively through 3D gamma passing rates at several selected acceptance criteria and qualitatively through the evaluation of dose-profiles, isodose-curves, and dose-volume histograms. We observed that the overall 3D gamma passing rate exceeded 90% at acceptance criteria of 2% dose difference and 2 mm distance-to-agreement for a dose threshold of 20%. The results of this study suggest that the polymer MAGIC-gel sealed in thin-wall glass spheres in conjunction with the optical CT readout method is a suitable PSQA system for SBRT treatments.

Detection of FLASH-radiotherapy tissue sparing in a 3D-spheroid model using DNA damage response markers

PurposeThe oxygen depletion hypothesis has been proposed as a rationale to explain the observed phenomenon of FLASH-radiotherapy (FLASH-RT) sparing normal tissues while simultaneously maintaining tumor control. In this study we examined the distribution of DNA Damage Response (DDR) markers in irradiated 3D multicellular spheroids to explore the relationship between FLASH-RT protection and radiolytic-oxygen-consumption (ROC) in tissues. Methods: Studies were performed using a Varian Truebeam linear accelerator delivering 10 MeV electrons with an average dose rate above 50 Gy/s. Irradiations were carried out on 3D spheroids maintained under a range of O2 and temperature conditions to control O2 consumption and create gradients representative of in vivo tissues. Results: Staining for pDNA-PK (Ser2056) produced a linear radiation dose response whereas γH2AX (Ser139) showed saturation with increasing dose. Using the pDNA-PK staining, radiation response was then characterised for FLASH compared to standard-dose-rates as a function of depth into the spheroids. At 4 °C, chosen to minimize the development of metabolic oxygen gradients within the tissues, FLASH protection could be observed at all distances under oxygen conditions of 0.3–1 % O2. Whereas at 37 °C a FLASH-protective effect was limited to the outer cell layers of tissues, an effect only observed at 3 % O2. Modelling of changes in the pDNA-PK-based oxygen enhancement ratio (OER) yielded a tissue ROC g0-value estimate of 0.73 ± 0.25 µM/Gy with a km of 5.4 µM at FLASH dose rates. Conclusions: DNA damage response markers are sensitive to the effects of transient oxygen depletion during FLASH radiotherapy. Findings support the rationale that well-oxygenated tissues would benefit more from FLASH-dose-rate protection relative to poorly-oxygenated tissues.

A comprehensive Study of the Out of Field Non Target Dose Associated with 6 and 10 MV Flattened and Flattening Filter Free X Ray Beam in a True Beam Linear Accelerator.

To evaluate the out-of-field dose associated with flattened (FF) and flattening filter-free (FFF) 6 and 10 MV X-ray beams in a TrueBeam linear accelerator (Linac). Measurements were taken in a slab phantom using the metal oxide semiconductor field effect transistor (MOSFET) detector at varying depths (dmax, 5 cm, and 10 cm) for clinically relevant field sizes and up to 30 cm from the field edges for 6 and 10 MV FF and FFF beams in TrueBeam Linac. Dose calculation accuracy of the analytic anisotropic algorithm (AAA) and Acuros algorithm was investigated in the out-of-field region. Similarly, the out-of-field dose associated with volumetric modulated arc therapy (VMAT) head-and-neck plan delivered to a body phantom was evaluated. The out-of-field dose for both FF and FFF photon beams (6 and 10 MV) decreased with increasing distance from the field boundary and size. Furthermore, regardless of FF in the field, higher-energy photon beams were associated with lower out-of-field dose. Both algorithms underestimated the dose in the out-of-field region, with AAA failing to calculate the out-of-field dose at 15 cm from the field edge and Acuros failing to calculate out-of-field radiation at 20 cm. At 5 cm from the field edge, an average of 50% underestimation was observed, and at 10 cm, an average of 60% underestimation was observed for both FF and FFF (6 and 10 MV) beams. The VMAT head-and-neck plan performed with the FFF beam resulted in a lower out-of-field dose than the FF beam for a comparable dose distribution. Compared with flattened beams, the FFF modes on TrueBeam Linac exhibited a clinically relevant reduction in the out-of-field dose. Further dosimetric studies are warranted to determine the significant benefit of FFF beams across different cancer sites.

Estimation of organ and effective doses of CBCT scans of radiotherapy using size-specific field of view (FOV): a Monte Carlo study.

The kV cone beam computed tomography (CBCT) is one of the most common imaging modalities used for image-guided radiation therapy (IGRT) procedures. Additional doses are delivered to patients, thus assessment and optimization of the imaging doses should be taken into consideration. This study aimed to investigate the influence of using fixed and patient-specific FOVs on the patient dose. Monte Carlo simulations were performed to simulate kV beams of the imaging system integrated into Truebeam linear accelerator using BEAMnrc code. Organ and size-specific effective doses resulting from chest and pelvis scanning protocols were estimated with DOSXYZnrc code using a phantom library developed by the National Cancer Institute (NCI) of the US. The library contains 193 (100 male and 93 female) mesh-type computational human adult phantoms, and it covers a large ratio of patient sizes with heights and weights ranging from 150 to 190cm and 40 to 125kg. The imaging doses were assessed using variable FOV of three sizes, small (S), medium (M), and large (L) for each scan region. The results show that the FOV and the patient size played a major role in the scan dose. The average percentage differences (PDs) for doses of organs that were fully inside the different FOVs were relatively low, all within 11% for both protocols. However, doses to organs that were scanned partially or near the FOVs were affected significantly. For the chest protocol, the inclusion of the thyroid in the scan field could give a dose of 1-7mGy/100mAs to the thyroid, compared to 0.4-1mGy/100mAs when it was excluded. Similarly, on average, testes doses could be 6mGy/100mAs for the male pelvis protocol compared to 3mGy/100mAs when it did not lie in the field irradiated. These dose differences resulted in an average increase of up to 27% in the size-specific effective dose of the protocols. Since changing the field size is possible for CBCT scans, the results suggest that patient-specific scanning protocols could be applied for each scan area in a manner similar to that used for CT scans. Adjustment of the FOV size should be subject to the clinical needs, and assist in improving the treatment accuracy. The patient's height and weight might be considered as the main factors upon which, the selection of the appropriate patient-specific protocol is based. This approach should optimize the imaging doses used for IGRT procedures by minimizing doses of a large ratio of patients.

Evaluating the Efficacy of Machine Performance Checks as an Alternative to Winston-Lutz Quality Assurance Testing in the TrueBeam Linear Accelerator with HyperArc.

HyperArc is a preferred technique for treating brain metastases, employing a single isocenter for multiple lesions. Geometrical isocentricity in the TrueBeam linear accelerator with HyperArc is crucial. We evaluated machine performance checks (MPCs) as an alternative to the Winston-Lutz (WL) test to verify the treatment isocenter. Between January and July 2023, we assessed 53 data points using MPC and Winston-Lutz tests. The isocenter size obtained from the MPC and its sum, including the rotation-induced couch shift, were compared with the maximum total delta value from the Winston-Lutz test. The maximum total delta was 0.68 ± 0.10 mm, while the isocenter size was 0.28 ± 0.02 mm. The sum of the isocenter size and rotation-induced couch shift measured by MPC was 0.61 ± 0.03 mm. During the Winston-Lutz test (without couch rotation), the maximum total delta value was 0.56 ± 0.13 mm. A t-test analysis revealed a significant difference in the isocenter size averages between the Winston-Lutz and MPC outcomes, whereas the Pearson's correlation coefficient yielded no correlation. Our study highlights the necessity for separate MPC and Winston-Lutz tests for isocenter verification. Therefore, the Winston-Lutz test should precede stereotactic radiosurgery for isocenter verification.

Multi-point calorimeter using distributed fiber Bragg gratings for small field dosimetry in radiotherapy.

The interest of using fiber Bragg gratings (FBGs) dosimeters in radiotherapy (RT) lies in their (i) microliter detection volume, (ii) customizable spatial resolution, (iii) multi-point dose measurement, (iv) real-time data acquisition and (v) insensitivity to Cherenkov light. These characteristics could prove very useful for characterizing dose distributions of small and nonstandard fields with high spatialresolution. We developed a multi-point FBGs dosimeter customized for small field RT dosimetry with a spatial resolution of 1mm. The 3cm-long multi-point dosimeter is made by embedding a 80 silica fiber containing an array of thirty (30) co-located 1mm-long fs-written FBGs inside a plastic cylinder with an UV curing optical adhesive. With its higher thermal expansion coefficient, the plastic cylinder increases the sensitivity of the dosimeter by stretching the fiber containing the FBGs when the temperature rises slightly due to radiation energy deposition. Irradiations (2000MU at 600MU/min) were performed with a Varian TrueBeam linearaccelerator. The dose profile of a 2 2cm 6MV beam was measured with a mean relative difference of 1.8% (excluding the penumbra region). The measured output factors for a 6MV beam are in general agreement with the expected values within the experimental uncertainty (except for the 2 2cm field). The detector response to different energy of photon and electron beams is within 5% of the mean response ( pm/Gy). The calorimeter's post-irradiation thermal decay is in agreement with thetheory. An energy-independent small field calorimeter that allows dose profile and output factor measurements for RT using FBGs was developed, which, to our knowledge, has never been done before. This type of detector could prove really useful for small field dosimetry, but also potentially for MRI-LINAC since FBGs are insensitive to magnetic fields and for FLASH since FBGs have been used to measure doses up to100kGy.

Single isocenter versus dual isocenter treatment using flattening filter-free and jaw-tracking volumetrically modulated arc therapy for boot-shaped lung cancer: Evaluation of dosimetric and feasibility.

To determine whether a dual-isocenter volumetrically modulated arc therapy (VMAT) technique results in lower normal pulmonary dosage compared to a traditional single isocenter technique for boot-shaped lung cancer. A cohort of 15 patients with advanced peripheral or central lung cancer who had metastases in the mediastinum and supraclavicular lymph nodes was randomly selected for this retrospective study. VMAT plans were generated for each patient using two different beam alignment techniques with the 6-MV flattening filter-free (FFF) photon beam: single-isocenter jaw-tracking VMAT based on the Varian TrueBeam linear accelerator (S-TV), and dual-isocenter VMAT based on both TrueBeam (D-TV) and Halcyon linear accelerator (D-HV). For all 45 treatment plans, planning target volume (PTV) dose coverage, conformity/homogeneity index (CI/HI), mean heart dose (MHD), mean lung dose (MLD) and the total lung tissue receiving 5, 20, 30Gy (V5, V20, V30) were evaluated. The monitor units (MUs), delivery time, and plan quality assurance (QA) results were recorded. The quality of the objectives of the three plans was comparable to each other. In comparison with S-TV, D-TV and D-HV improved the CI and HI of the PTV (p<0.05). The MLD was 13.84±1.44Gy (mean±SD) for D-TV, 14.22±1.30Gy and 14.16±1.42Gy for S-TV and D-HV, respectively. Lungs-V5Gy was 50.78±6.24%, 52.00±7.32% and 53.36±8.48%, Lungs-V20Gy was 23.72±2.27%, 26.18±2.86% and 24.96±3.09%, Lungs-V30Gy was 15.69±1.76%, 17.20±1.72% and 16.52±2.07%. Compared to S-TV, D-TV provided statistically significant better protection for the total lung, with the exception of the lungs-V5. All plans passed QA according the gamma criteria of 3%/3mm. Taking into account the dosimetric results and published clinical data on radiation-induced pulmonary injury, dual-isocenter jaw-tracking VMAT may be the optimal choice for treating boot-shaped lung cancer.

Comparison of skin dose in IMRT and VMAT with TrueBeam and Halcyon linear accelerator for whole breast irradiation

With the increasing use of flattening filter free (FFF) beams, it is important to evaluate the impact on the skin dose and target coverage of breast cancer treatments. This study aimed to compare skin doses of treatments using FFF and flattening filter (FF) beams for breast cancer. The study established treatment plans for left breast of an anthropomorphic phantom using Halcyon’s 6-MV FFF beam and TrueBeam’s 6-MV FF beam. Volumetric modulated arc therapy (VMAT) with varying numbers of arcs and intensity modulated radiation therapy (IMRT) were employed, and skin doses were measured at five points using Gafchromic EBT3 film. Each measurement was repeated three times, and averaged to reduce uncertainty. All plans were compared in terms of plan quality to ensure homogeneous target coverage. The study found that when using VMAT with two, four, and six arcs, in-field doses were 19%, 15%, and 6% higher, respectively, when using Halcyon compared to TrueBeam. Additionally, when using two arcs for VMAT, in-field doses were 10% and 15% higher compared to four and six arcs when using Halcyon. Finally, in-field dose from Halcyon using IMRT was about 1% higher than when using TrueBeam. Our research confirmed that when treating breast cancer with FFF beams, skin dose is higher than with traditional FF beams. Moreover, number of arcs used in VMAT treatment with FFF beams affects skin dose to the patient. To maintain a skin dose similar to that of FF beams when using Halcyon, it may be worth considering increasing the number of arcs.

Comparison of Rapid Arc and Intensity Modulated Radiotherapy in a True Beam Linear Accelerator for 6 MV: Application of AAPM TG‐119 tests in treatment planning and quality assurance

AbstractObjectiveWe developed rapid arc (RA) and intensity‐modulated radiotherapy (IMRT) plans based on the American Association of Physicists in Medicine Task Group‐119 (AAPM TG‐119) proposals and compared the planning and quality assurance results.Materials and MethodsTwo treatment plans were used for each study patient: one using 7–9 IMRT fields and the other using the two full‐arc RA methods. Plan optimization and dose calculations were performed using 6 MV photons and EclipseTM with the anisotropic analytical algorithm (AAA). Task group (TG)‐119 described the planning objectives used to evaluate the treatment plans generated for this study. Point dose, planar fluence measurement, and trajectory log file analysis are used for quality assurance.ResultsThe conformity index (CI) for treatment plans varied between 0.76–0.91 when using IMRT and 0.75–0.93 when using RA. The homogeneity index (HI) was approximately 0.10–0.24 (IMRT) and 0.07–0.23 (RA). The ratio of the total number of monitor units required for IMRT to that required for RA was between 0.87 and 2.14. The treatment log files exhibited higher gamma passing with RA than with IMRT.ConclusionRA plans were more effective than IMRT plans in achieving the test goals. Point dose measurements and electronic portal imaging device (EPID)‐based planar fluence measurements showed statistically insignificant differences between the IMRT and RA plan quality assurance (QA) results. However, the trajectory log file analysis exhibited better gamma‐passing results for RA than for IMRT.